pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Taltz
drug
save

ixekizumab

Marketedupdated 3mo ago
by Eli Lilly and Co
Approved
community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying ixekizumab

  • phase3A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapyactive not recruitingn=308
  • phase3A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritisactive not recruitingn=101
  • N/ACombination of Biologic and Anti-obesity Therapies in Psoriatic Arthritisnot yet recruitingn=45
  • phase3Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweightactive not recruitingn=279
  • phase3Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweightactive not recruitingn=250
  • phase1Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjectsactive not recruitingn=218
  • phase4A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in Indiacompletedn=250
  • phase4COVID-19 VaccinE Response in Rheumatology Patientscompletedn=841
more trials →

News(0)

no news has mentioned this drug yet

brand
Taltz
generic
ixekizumab
indication
Plaque Psoriasis (Psoriasis Vulgaris)
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 55m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?